Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Cell-Based Therapies

Background:

• Peripheral Artery Disease (PAD) with Chronic Limb Threatening Ischemia (CLTI) is a severe condition often unresponsive to standard treatments, leading to amputation risk.
• Conventional surgical, endovascular, and medical therapies can be insufficient for managing advanced PAD with CLTI.

Purpose of the Study:

• To review current knowledge on autologous cell therapy and regenerative medicine for PAD with CLTI.
• To evaluate the role of cell-based therapies in promoting angiogenesis, vascular restoration, and tissue regeneration.
• To provide an overview of key clinical studies and factors influencing treatment success.

Main Methods:

• Literature review of recent studies on autologous cell-based therapies for PAD with CLTI.
• Evaluation of clinical trials and their outcomes.
• Analysis of patient-specific factors influencing therapeutic performance.

Main Results:

• Cell-based therapies demonstrate potential in promoting vascular repair and tissue regeneration in PAD with CLTI.
• Patient clinical conditions and risk factors significantly correlate with the efficacy and success rates of autologous cell therapies.
• Current evidence suggests these regenerative approaches are promising, though further investigation is warranted.

Conclusions:

• Autologous cell therapy and regenerative medicine offer a promising adjunct for treating PAD with CLTI.
• Personalized medicine approaches, considering individual patient profiles, are crucial for tailoring these advanced therapies.
• Continued research and clinical studies are necessary to fully establish the role of these techniques in clinical practice.